(CercleFinance.com) – Pfizer announced on Friday that US and European health authorities had agreed to assess its application for registration of ritlecitinib, an experimental treatment for alopecia, a disease characterized by hair loss.
The biopharmaceutical group specifies that the acceptance of the FDA concerns the use of the drug in adults and adolescents over 12 years old affected by alopecia areata, a pathology commonly known as alopecia areata and which manifests itself by a sudden hair loss.
The FDA’s final decision is expected in the second quarter of 2023.
As for the European Medicines Agency (EMA), it has planned to look into the file in the same indication with a decision scheduled for the fourth quarter of 2023, continues the laboratory.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
